Deals & M&A
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
With accelerated approval in advanced urothelial cancer, the sponsors now have data that could support full approval plus a move into first-line therapy.
Plus deals involving Debiopharm/SunRock, RefleXion/3B Pharmaceuticals, Pharmanovia/Sanofi and more.
Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”
Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.
The Swiss drug maker’s decision to give back rights to tislelizumab means BeiGene goes without the potentially $1.55bn in milestone payments the companies had agreed to in early 2021.
Sun debuts Pharmazz Inc’s new stroke drug sovateltide in India at under $20/ vial. The selective endothelin-B receptor agonist, which can be administered up to 24 hours post cerebral ischemic stroke, is also being studied in Alzheimer’s disease.
Bristol aims to bring more drugs into the clinic as fast as possible without compromising on quality, with many novel molecules emerging from its productive protein degradation and cell therapy platforms.
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
First Wave is licensing Sanofi’s 5-HT4 receptor partial agonist capeserod and is having to pay a mere $500,000 in upfront fees for the privilege.
Harpoon said it plans to complete the Phase I study of its anti-BCMA immuno-oncology agent HPN217 and use the data to support the next phase of development for the drug.
MSD and Astellas have joined Lilly, Takeda and AstraZeneca in making major investments in Ireland this year.
A Chinese court decision sheds light on how Chinese major Hengrui Medicine is seeking to reduce or avoid potential losses worth up to $27m following regulatory setbacks with the tubulin inhibitor plinabulin, in-licensed from BeyondSpring in 2021.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.